ANIK · Anika Therapeutics Inc
United States · RS rating 86 · As of 2026-11-03
| Price | 19.45 USD |
|---|---|
| 1-day change | +0.2% |
| RS rating (overall / 1M / 3M / 12M) | 86 / 52 / 70 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 39 / 46 / 58 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +112.5% |
| Sales growth Q/Q | +10.1% |
| Distance from 52-week high | +11.7% |
| Market cap (USD) | $222.4M |